Article PDF
Avoid common mistakes on your manuscript.
References
Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, ABeta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99–102.
Schenk D, Barbour R, Dunn W, et al. Iimmunization with amyloid-beta attenuates alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173–177.
Schenk D. Amyloid-beta immunotherapy for Alzheimer’s disease: the end of the beginning. Nature reviews Neuroscience 2002;3:824–828.
Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061–2070.
Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012;11:241–249.
Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB Pet assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363–372.
Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with alzheimer’s disease. Alzheimers Dement 2012;8:261–271.
Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. The Journal of neuroscience: the official journal of the Society for Neuroscience 2012;32:9677–9689.
Colombia at the centre of preclinical AD research. Lancet Neurol 2012;11:567.
Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;69:198–207.
Sperling RA, Jack CR, Jr., Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011;3:111cm133.
Vellas B, Hampel H, Rouge-Bugat ME, et al. Alzheimer’s Disease Therapeutic Trials: EU/US Task Force Report on Recruitment, Retention, and Methodology. J Nutr Health Aging. 2012 Apr;16(4):339–345.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aisen, P.S., Vellas, B. Passive immunotherapy for Alzheimer’s disease: What have we learned, and where are we headed?. J Nutr Health Aging 17, 49–50 (2013). https://doi.org/10.1007/s12603-013-0001-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12603-013-0001-3